Answers are grounded in this paper and cite their sources.
Background The positive and negative syndrome scale (PANSS) has long been used in the assessment of patients with schizophrenia; however, its lengthy administration process, which can even exceed an hour, has led to interest in developing a shorter version. PANSS-6 was created as a more efficient and streamlined alternative, and in this study, we aimed to evaluate its application in assessing severity and improvement in patients with schizophrenia undergoing a multicenter, open-label study of paliperidone. Methods A total of 271 patients aged 18–60 years with a DSM-IV diagnosis of schizophrenia participated in the study. Over a 6-week observation period, patients received paliperidone monotherapy and underwent clinical assessments using PANSS. The study conducted a comprehensive analysis of internal consistency, the effectiveness of antipsychotic treatment, response and remission assessments, and early response prediction, comparing PANSS-6 with PANSS-30. Results PANSS-6 showed good reliability and was highly correlated with PANSS-30. It was effective in evaluating the severity of schizophrenia and monitoring the score reduction over time. We observed no significant difference in the mean effect sizes (ES) between PANSS-6 and PANSS-30. Furthermore, using PANSS-6, early response at week 2 was found to be predictive of ultimate response and remission at week 6. Conclusion In this study, PANSS-6 demonstrated good internal consistency and a strong correlation with PANSS-30. These findings support its value for assessing treatment outcomes and predicting early response in patients with schizophrenia undergoing antipsychotic therapy. The use of PANSS-6 may offer a practical and streamlined method for symptom monitoring in clinical settings. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: